We suggest that the regimen of immunosuppressive drugs
Infections in patients receiving immunosuppressive drugs are common, and such therapy may prevent signs of infection from developing by impairing immune activation and associated inflammatory responses typically associated with the infection in immunocompetent individuals. The infection may have been pre-existing, either as an incidental latent infection or masquerading as primary autoimmunity and may only become detectable as a result of therapy. More commonly, de-novo infections develop as a consequence of therapy. Pre-treatment factors and comorbidities increasing the risk of infection developing when immunosuppressive drugs are started include latent infections, presence of surgical implants, severe osteoarthritis, skin disease, dental disease, airway compromise and congenital heart defects. Additional risk factors that may be present in IMHA patients include intravenous and urinary catheters, feeding tubes, prolonged recumbency, and gastrointestinal compromise (poor perfusion, ulceration, vomiting). There may be considerable overlap in symptoms caused by infection, immunosuppressive therapy, and IMHA or its complications. For example, tachypnea can be caused by anemia, glucocorticoid therapy, pulmonary thromboembolism, or infectious bronchopneumonia.
Depending on geographic location, travel history and potential for tick exposure, ongoing monitoring for emergence of vector-borne disease should also be considered during immunosuppressive therapy.
Opportunistic fungal infections and protozoal infections appear to be more common with use of cyclosporine than with other immunosuppressive drugs a,b . The numerous permutations of infection in IMHA patients make it difficult to design a universal treatment algorithm to cover every eventuality.
Important considerations concerning the infection include:
• Whether infection is suspected or has been confirmed and the identification of the infectious organism(s)
• Patient welfare and prognosis -for example, aortic valve endocarditis carries a poor prognosis even in the absence of immunosuppressive therapy • When to change the immunosuppressive dose -if IMHA is likely to kill the patient before the infection does, the dose should not be reduced
